{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer's disease", "BACE1", "cholinesterase", "chromenone", "coumarin", "docking", "isoxazole", "metal chelating", "neuroprotectivity"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32154628", "DateCompleted": {"Year": "2021", "Month": "01", "Day": "04"}, "DateRevised": {"Year": "2021", "Month": "01", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "04", "Day": "15"}], "Language": ["eng"], "ELocationID": ["10.1002/cbdv.201900746"], "Journal": {"ISSN": "1612-1880", "JournalIssue": {"Volume": "17", "Issue": "5", "PubDate": {"Year": "2020", "Month": "May"}}, "Title": "Chemistry & biodiversity", "ISOAbbreviation": "Chem Biodivers"}, "ArticleTitle": "Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease.", "Pagination": {"StartPage": "e1900746", "MedlinePgn": "e1900746"}, "Abstract": {"AbstractText": ["A novel series of hybrid arylisoxazole-chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase (ChE) inhibitory activity based on the modified Ellman's method. Among synthesized compounds, 5-(3-nitrophenyl)-N-{4-[(2-oxo-2H-1-benzopyran-7-yl)oxy]phenyl}-1,2-oxazole-3-carboxamide depicted the most acetylcholinesterase (AChE) inhibitory activity (IC<sub>50</sub> =1.23\u2005\u03bcm) and 5-(3-chlorophenyl)-N-{4-[(2-oxo-2H-1-benzopyran-7-yl)oxy]phenyl}-1,2-oxazole-3-carboxamide was found to be the most potent butyrylcholinesterase (BChE) inhibitor (IC<sub>50</sub> =9.71\u2005\u03bcm). 5-(3-Nitrophenyl)-N-{4-[(2-oxo-2H-1-benzopyran-7-yl)oxy]phenyl}-1,2-oxazole-3-carboxamide was further investigated for its BACE1 inhibitory activity as well as neuroprotectivity and metal chelating ability as important factors involved in onset and progress of Alzheimer's disease. It could inhibit BACE1 by 48.46\u2009% at 50\u2005\u03bcm. It also showed 6.4\u2009% protection at 25\u2005\u03bcm and satisfactory chelating ability toward Zn<sup>2+</sup> , Fe<sup>2+</sup> , and Cu<sup>2+</sup> ions. Docking studies of 5-(3-nitrophenyl)-N-{4-[(2-oxo-2H-1-benzopyran-7-yl)oxy]phenyl}-1,2-oxazole-3-carboxamide and 5-(3-chlorophenyl)-N-{4-[(2-oxo-2H-1-benzopyran-7-yl)oxy]phenyl}-1,2-oxazole-3-carboxamide confirmed desired interactions with those amino acid residues of the AChE and BChE, respectively."], "CopyrightInformation": "\u00a9 2020 Wiley-VHCA AG, Zurich, Switzerland."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, 14155, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, 14155, Tehran, Iran."}], "LastName": "Saeedi", "ForeName": "Mina", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, 14155, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, 14155, Tehran, Iran."}], "LastName": "Rastegari", "ForeName": "Arezoo", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, 14155, Tehran, Iran."}], "LastName": "Hariri", "ForeName": "Roshanak", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Sciences, 14665, Tehran, Iran."}], "LastName": "Mirfazli", "ForeName": "Seyedeh Sara", "Initials": "SS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, 14155, Tehran, Iran."}], "LastName": "Mahdavi", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348, Shiraz, Iran."}], "LastName": "Edraki", "ForeName": "Najmeh", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348, Shiraz, Iran."}], "LastName": "Firuzi", "ForeName": "Omidreza", "Initials": "O"}, {"Identifier": ["0000-0002-0212-7297"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, 14155, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, 14155, Tehran, Iran."}], "LastName": "Akbarzadeh", "ForeName": "Tahmineh", "Initials": "T"}], "GrantList": [{"GrantID": "98-3-104-46061", "Agency": "Research Council of Tehran University of Medical Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Chem Biodivers", "NlmUniqueID": "101197449", "ISSNLinking": "1612-1872"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Cholinesterase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Chromones"}, {"RegistryNumber": "0", "NameOfSubstance": "Isoxazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Peptide Fragments"}, {"RegistryNumber": "0", "NameOfSubstance": "amyloid beta-protein (25-35)"}, {"RegistryNumber": "EC 3.1.1.7", "NameOfSubstance": "Acetylcholinesterase"}, {"RegistryNumber": "EC 3.1.1.8", "NameOfSubstance": "Butyrylcholinesterase"}], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Acetylcholinesterase"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Amyloid beta-Peptides"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Butyrylcholinesterase"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Cholinesterase Inhibitors"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Chromones"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Electrophorus"}, {"QualifierName": [], "DescriptorName": "Horses"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Isoxazoles"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": [], "DescriptorName": "PC12 Cells"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Peptide Fragments"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Alzheimer's association, \u20182016 Alzheimer's disease facts and figures\u2019, Alzheimer\u2032s Dementia 2016, 12, 459-509."}, {"Citation": "C. A. Lane, J. Hardy, J. M. Schott, \u2018Alzheimer's disease\u2019, Eur. J. Neurol. 2018, 25, 59-70."}, {"Citation": "R. S. Wilson, E. Segawa, P. A. Boyle, S. E. Anagnos, L. P. Hizel, D. A. Bennett, \u2018The natural history of cognitive decline in Alzheimer's disease\u2019, Psychol. Aging 2012, 27, 1008-1017."}, {"Citation": "X. Q. Chen, W. C. Mobley, \u2018Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses\u2019, Front. Neurol. Neurosci. 2019, 13, 446."}, {"Citation": "H. K. Lim, W. S. Jung, K. J. Ahn, W. Y. Won, C. Hahn, S. Y. Lee, I. Kim, C. U. Lee, \u2018Relationships between hippocampal shape and cognitive performances in drug-naive patients with Alzheimer's disease\u2019, Neurosci. Lett. 2012, 516, 124-129."}, {"Citation": "K.\u2005P. Mitchell, M.\u2005K.\u2005P. Lai, M.\u2005J. Ramirez, S.\u2005W.\u2005Y. Tsang, P.\u2005T. Francis, \u2018Alzheimer's disease as a neurotransmitter disease\u2019, in \u2018Neurobiology of Alzheimer's disease\u2019, Eds. D. Dawbarn, S.\u2005J. Allen, Oxford University Press, Oxford, 2009, pp. 245-282."}, {"Citation": "P. J. Whitehouse, D. L. Price, R. G. Struble, A. W. Clark, J. T. Coyle, M. R. Delon, \u2018Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain\u2019, Science 1982, 215, 1237-1239."}, {"Citation": "C. Geula, M. M. Mesulam, \u2018Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study\u2019, Neuroscience 1989, 33, 469-481."}, {"Citation": "E. K. Perry, R. H. Perry, G. Blessed, B. E. Tomlinson, \u2018Necropsy evidence of central cholinergic deficits in senile dementia\u2019, Lancet 1977, 1, 189."}, {"Citation": "P. Davies, A. J. Maloney, \u2018Selective loss of central cholinergic neurons in Alzheimer's disease\u2019, Lancet 1976, 2, 1403."}, {"Citation": "T. Arendt, M. K. Bruckner, M. Lange, V. Bigl, \u2018Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms\u2019, Neurochem. Int. 1992, 21, 381-396."}, {"Citation": "R. M. Lane, S. G. Potkin, A. Enz, \u2018Targeting acetylcholinesterase and butyrylcholinesterase in dementia\u2019, Int. J. Neuropsychopharmacol. 2006, 9, 101-124."}, {"Citation": "A. Hiremathad, L. Piemontese, \u2018 Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy\u2019, Neural Regen. Res. 2017, 12, 1256-1261."}, {"Citation": "L. G. de Souza, M. N. Renna, J. D. Figueroa-Villar, \u2018Coumarins as cholinesterase inhibitors: A review\u2019, Chem.-Biol. Interact. 2016, 254, 11-23."}, {"Citation": "L. Jalili-Baleh, H. Forootanfar, T. T. Kucukkilinc, H. Nadri, Z. Abdolahi, A. Ameri, M. Jafari, B. Ayazgok, M. Baeeri, M. Rahimifard, S. N. Abbas Bukhari, M. Abdollahi, M. R. Ganjali, S. Emami, M. Khoobi, A. Foroumadi, \u2018Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer's disease based on coumarin and lipoic acid scaffolds\u2019, Eur. J. Med. Chem. 2018, 152, 600-614."}, {"Citation": "F. Vafadarnejad, M. Mahdavi, E. Karimpour-Razkenari, N. Edraki, B. Sameem, M. Khanavi, M. Saeedi, T. Akbarzadeh, \u2018Design and synthesis of novel coumarin-pyridinium hybrids: In vitro cholinesterase inhibitory activity\u2019, Bioorg. Chem. 2018, 77, 311-319."}, {"Citation": "Z. Najafi, M. Mahdavi, M. Saeedi, R. Sabourian, M. Khanavi, M. Safavi, M. B. Tehrani, A. Shafiee, A. Foroumadi, T. Akbarzadeh, \u20181,2,3-Triazole-Isoxazole based acetylcholinesterase inhibitors: Synthesis, biological evaluation and docking study\u2019, Lett. Drug Des. Discovery 2017, 14, 58-65."}, {"Citation": "M. Saeedi, D. Mohtadi-Haghighi, S. S. Mirfazli, M. Mahdavi, R. Hariri, H. Lotfian, N. Edraki, A. Iraji, O. Firuzi, T. Akbarzadeh, \u2018Design and synthesis of selective acetylcholinesterase inhibitors: Arylisoxazole-Phenylpiperazine derivatives\u2019, Chem. Biodiversity 2019, 16, e1800433."}, {"Citation": "F. Vafadarnejad, M. Saeedi, M. Mahdavi, A. Rafinejad, E. Karimpour-Razkenari, B. Sameem, M. Khanavi, T. Akbarzadeh, \u2018Novel indole-isoxazole hybrids: synthesis and In Vitro anti-cholinesterase activity\u2019, Lett. Drug Des. Discovery 2017, 14, 712-717."}, {"Citation": "F. Vafadarnejad, E. Karimpour-Razkenari, B. Sameem, M. Saeedi, O. Firuzi, N. Edraki, M. Mahdavi, T. Akbarzadeh, \u2018Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study\u2019, Bioorg. Chem. 2019, 92, 103192."}, {"Citation": "T. Akbarzadeh, A. Rafinejad, J. M. Mollaghasem, M. Safavi, A. Fallah-Tafti, M. Pordeli, S. A. Kabudanian, A. Shafiee, A. Foroumadi, \u20182-Amino-3-cyano-4-(5-arylisoxazol-3-yl)-4H-chromenes: Synthesis and in\u2005vitro cytotoxic activity\u2019, Arch. Pharm. 2012, 345, 386-392."}, {"Citation": "K. Setsukinai, Y. Urano, K. Kikuchi, T. Higuchi, T. Nagano, \u2018Fluorescence switching by O-dearylation of 7-aryloxycoumarins. Development of novel fluorescence probes to detect reactive oxygen species with high selectivity\u2019, J. Chem. Soc. Perkin Trans. 1 2000, 2, 2453-2457."}, {"Citation": "Z. Najafi, M. Saeedi, M. Mahdavi, R. Sabourian, M. Khanavi, M. B. Tehrani, F. H. Moghadam, N. Edraki, E. Karimpor-Razkenari, M. Sharifzadeh, A. Foroumadi, A. Shafiee, T. Akbarzadeh, \u2018Design and synthesis of novel anti-Alzheimer's agents: Acridine-chromenone and quinoline-chromenone hybrids\u2019, Bioorg. Chem. 2016, 67, 84-94."}, {"Citation": "A. Iraji, O. Firuzi, M. Khoshneviszadeh, M. Tavakkoli, M. Mahdavi, H. Nadri, N. Edraki, R. Miri, \u2018Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease\u2019, Eur. J. Med. Chem. 2017, 141, 690-702."}, {"Citation": "J. Chlebek, J. Korabecny, R. Dolezal, S. Stepankova, D. I. Perez, A. Hostalkova, L. Opletal, L. Cahlikova, K. Macakova, T. Kucera, M. Hrabinova, D. Jun, \u2018In Vitro and in silico acetylcholinesterase inhibitory activity of thalictricavine and canadine and their predicted penetration across the blood-brain barrier\u2019, Molecules 2019, 24."}, {"Citation": "R. Quiroga, M. A. Villarreal, \u2018Vinardo: A scoring function based on autodock vina improves scoring, docking, and virtual screening\u2019, PLoS One 2016, 11, e0155183."}, {"Citation": "S. K. Yusufzai, M. S. Khan, O. Sulaiman, H. Osman, D. N. Lamjin, \u2018Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and beta-amyloid inhibitors for Alzheimer's disease\u2019, Chem. Cent. J. 2018, 12, 128."}, {"Citation": "G. L. Ellman, K. D. Courtney, V. Andres\u2005Jr., R. M. Feather-Stone, \u2018A new and rapid colorimetric determination of acetylcholinesterase activity\u2019, Biochem. Pharmacol. 1961, 7, 88-95."}, {"Citation": "M. Karamac, \u2018Chelation of Cu(II), Zn(II), and Fe(II) by tannin constituents of selected edible nuts\u2019, Int. J. Mol. Sci. 2009, 10, 5485-5497."}]}], "History": [{"Year": "2019", "Month": "12", "Day": "31"}, {"Year": "2020", "Month": "3", "Day": "9"}, {"Year": "2020", "Month": "3", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "3", "Day": "11", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32154628", "10.1002/cbdv.201900746"]}}]}